China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 2.2 chemical octreotide long-acting injection in acromegaly. This marks a significant step forward in developing more convenient treatment options for patients with this rare condition.
Current Treatment Landscape
Octreotide is a first-line treatment for acromegaly and neuroendocrine tumors, currently available in China as short-acting injections and long-acting injectable microspheres. Short-acting injections require 2-3 administrations per day, leading to poor patient compliance. Long-acting microspheres, while administered monthly, face challenges such as complex preparation, injection pain, and high costs, limiting their widespread use.
CSPC’s Long-Acting Injection
CSPC’s octreotide long-acting injection aims to address these challenges by offering a once-monthly dosage form that improves convenience and patient compliance. The product has demonstrated superior bioavailability compared to injectable microspheres, without introducing new toxic target organs. This advancement positions CSPC’s long-acting injection as a potential game-changer in the treatment of acromegaly.-Fineline Info & Tech
